Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00922623 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI
A NA study, sponsored by Merz North America.
- Completed
- Registry status
- NA
- Development phase
- 93
- Enrollment target
NCT00922623: Completed NA study, sponsored by Merz North America.
NCT00922623 is a NA study that has completed, run by Merz North America. The registered enrollment target is 93 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00922623, a NA study, has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- NA
- Development phase
- 93 participants
- Enrollment target
Study Summary
This is a study to assess how safe and effective an investigational product, Belotero® is in people with all skin types with facial wrinkles, such as nasolabial folds. Nasolabial folds are wrinkles on the face that go from outside of the nostrils to the edges of the mouth.
Primary Outcome
Adverse events considered possibly, probably, or definitely related to study product are summarized by body system and MedDRA preferred term.
Interventions
- DEVICE Belotero®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-07 |
| Phase | NA |
What the finished NCT00922623 record still lists
NCT00922623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Belotero® is the first listed.
NCT00922623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00922623 about?
NCT00922623 is a clinical study titled "Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI". This is a study to assess how safe and effective an investigational product, Belotero® is in people with all skin types with facial wrinkles, such as nasolabial folds. Nasolabial folds are wrinkles on the face that go from outside of the nostrils to the edges of the mouth.
What is the current status of trial NCT00922623?
This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2009-05. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00922623?
The interventions under investigation include: Belotero® (DEVICE).
Who is sponsoring clinical trial NCT00922623?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00922623's enrollment target sits among peer trials
93 937th of 2000 higher than 1,064 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia